Uncategorized
Goldman Sachs Stays On The Sidelines On Exxon Mobil – Here’s Why
Goldman Sachs analyst cuts ExxonMobil price forecast due to mark-to-market commodity prices, but maintains Neutral rating. Q4 earnings expected on Jan 31, 2025. Latest Ratings for XOM Date Firm Action From To Mar 2022 Wells Fargo Maintains Overweight Mar 2022 MKM Partners Maintains Buy Mar 2022 BMO Capital Maintains Market Perform View More Analyst Ratings…
SLM’s Loan Growth And Expense Control In Focus, Analysts Adjust Price Forecasts
Wall Street raised SLM’s price targets after Q4 earnings release. EPS missed, but fiscal 2025 outlook higher than estimates. Analysts maintain ratings. Latest Ratings for SLM Date Firm Action From To Oct 2021 RBC Capital Maintains Outperform Oct 2021 Credit Suisse Maintains Outperform Oct 2021 Stephens & Co. Maintains Overweight View More Analyst Ratings for…
Thornburg ETF Debut: First Funds Target Global Equities With Active Strategies
Thornburg Investment Management launched its first two international equity ETFs with a focus on developed markets. Active management and low fees. read more
Forget Worrying About Bitcoin Going Down 50%, There’s Now A ‘Protected Bitcoin ETF’ With Money-Back Guarantee
Calamos Investments has introduced a suite of Protected Bitcoin Exchange-Traded Funds (ETFs), designed to offer exposure to Bitcoin (CRYPTO: BTC) while minimizing risk. read more
BYD, Geely, SAIC Contest EU’s High EV Tariffs In Court
Chinese EV makers BYD, Geely, and SAIC contested EU’s import duties at Court of Justice. Tesla excluded from tariffs, gaining only 7.8% tax. read more
Is SoFi Overheating? Strong Bullish Trend Meets Analyst Caution Ahead Of Q4 Earnings
SoFi (SOFI) reports Q4 earnings on Monday with expected EPS of 4 cents and revenue of $674.13 million. Stock is up 28.91% YTD. Analysts see 29% downside potential for stock with current consensus rating of Buy and price target of $10.33. read more
Allurion Technologies Shares Are Up Today: What’s Going On?
Allurion Technologies (NYSE: ALUR) shares are moving higher Friday potentially after after the company announced plans to conduct a clinical study evaluating the combination of its Allurion Program with GLP-1 agonists on Thursday. read more